Work

Long-term duration of axitinib treatment in advanced renal cell carcinoma

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw373.52

Authors: B.I. Rini, V. Grünwald, E. Jonasch, M.N. Fishman, Y. Tomita, M.D. Michaelson, J. Tarazi, L. Cisar, A.H. Blair, B. Rosbrook, T. Hutson

Institutions: Cleveland Clinic, Medizinische Hochschule Hannover, The University of Texas MD Anderson Cancer Center, University of South Florida, Moffitt Cancer Center, Niigata University, Massachusetts General Hospital, Pfizer (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, Astellas Pharma US, AstraZeneca, Novartis, Roche, Wyeth, North Carolina GlaxoSmithKline Foundation, Bayer Corporation, Prometheus, Exelixis, GlaxoSmithKline Australia

OpenAlex ID: W2588958718

FWCI:

Cites:

Cited by:

Related to: 10